EFTR
eFFECTOR Therapeutics Inc

2,424
Loading...
Loading...
News
all
press releases
Why eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%
EFFECTOR Therapeutics shares are trading lower by 74% during Monday's session. The company announced that it has terminated its employees and will wind down its operations. read more...
Benzinga·1y ago
News Placeholder
More News
News Placeholder
eFFECTOR Therapeutics trading resumes
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator...
Globe Newswire·1y ago
News Placeholder
eFFECTOR Therapeutics trading halted, news pending
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
eFFECTOR Therapeutics (NASDAQ:EFTR) Stock Rating Reaffirmed by HC Wainwright
eFFECTOR Therapeutics (NASDAQ:EFTR - Get Free Report)s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on...
Zolmax·1y ago
News Placeholder
eFFECTOR Therapeutics (NASDAQ:EFTR) Earns Buy Rating from HC Wainwright
eFFECTOR Therapeutics (NASDAQ:EFTR Get Free Report)s stock had its buy rating reissued by equities researchers at HC Wainwright in a note issued to investors on Thursday...
Ticker Report·1y ago
News Placeholder
Buy Rating for eFFECTOR Therapeutics Backed by Solid Financials and Promising Zotatifin Trials
Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on eFFECTOR Therapeutics (EFTR Research Report). The associated price ta...
TipRanks Financial Blog·1y ago
News Placeholder
eFfector Therapeutics reports Q4 EPS ($3.42), consensus ($1.65)
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024 Median progression free...
Globe Newswire·1y ago
News Placeholder
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator...
Globe Newswire·2y ago

Latest EFTR News

View

Advertisement. Remove ads.

Advertisement. Remove ads.